Cencora, Inc. · NYSE:COR
Cencora — AmerisourceBergen — Q1 FY2019 Earnings Presentation
13 slides from Cencora's earnings presentation, Jan 31, 2019
Slide 1: Q1 FY2019 Financial Results
Q1 FY2019 Financial Results January 31, 2019
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements Certain of the statements contained in this presentation are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as "expect," "likely," "ou
Slide 3: AmerisourceBergen is united in our responsibility to create healthier futures
AmerisourceBergen is united in our responsibility to create healthier futures. AmerisourceBergen drives innovative partnerships with global manufacturers, providers and pharmacies to improve product access and efficiency throughout the healthcare supply chain. 3
Slide 4: Q1 FY2019 Financial Results: Overview
Q1 FY2019 Financial Results: Overview • Strong results from our core Pharmaceutical Distribution businesses helped offset the significant headwind caused AmerisourceBergen by PharMEDium delivered solid results • Share repurchases and tax reform helped drive EPS growth • Double-digit revenue growth S
Slide 5: Q1 FY2019 Financial Results
Q1 FY2019 Financial Results Adjusted GAAP (non-GAAP)1 Revenue $45.4B $45.4B % Change (Year-over-Year) 12.2% 12.2% Gross Profit $1.3B $1.2B % Change 16.6% 8.1% Operating Expenses $820M $731M % Change 18.2% 17.1% Operating Income $478M $472M % Change 14.0% (3.3)% Interest Expense, Net $42M $42M % Chan
Slide 6: Pharmaceutical Distribution Services Segment
Q1 FY2019 Financial Results: Pharmaceutical Distribution Services Segment Q1 FY2019 Q1 FY2018 Revenue $43.7B $38.9B Operating Income $373.2M $388.2M Percentages of Revenue Gross Profit 2.01% 2.04% Operating Expenses 1.16% 1.04% Operating Income 0.85% 1.00% Continued growth of several of our larges
Slide 7: Other Businesses – Global Commercialization Services & Animal Health
Q1 FY2019 Financial Results: Other Businesses – Global Commercialization Services & Animal Health Q1 FY2019 Q1 FY2018 Revenue $1.7B $1.5B Operating Income $98.9M $100.3M Percentages of Revenue Gross Profit 19.45% 20.75% Operating Expenses 13.53% 14.26% Operating Income 5.92% 6.49% Other includes W
Slide 8: Differentiated and positioned for growth
Differentiated and positioned for growth Customer Base Innovative Services & • Key anchor customers Solutions • Fast growing • Customer-focused offerings • U.S. Pharmaceutical focus serving manufacturers and provider customers Leadership in Specialty Successful Financial Distribution & Services Stew
Slide 9: FY19 Financial Guidance
FY19 Financial Guidance Expectations on an Adjusted (non-GAAP) Basis(1),(2) Revenue Mid-single digit percent growth Diluted Earnings Per Share $6.65 to $6.85 Operating Expense Mid-single digit percent growth Low-single digit percent Operating Income growth Pharmaceutical Distribution Services Low-si
Slide 10: Appendix
Appendix N) AmerisourceBergen’
Slide 11: Appendix
Appendix Note: For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of the Company’s most recent Current Report on Form 8-K furnished under Item 2.02. 11
Slide 12: Appendix
Appendix Note: For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of the Company’s most recent Current Report on Form 8-K furnished under Item 2.02. 12
Slide 13: AmerisourceBergen
N) AmerisourceBergen’ Where knowledge, reach and partnership shape healthcare delivery.